New drug cocktail proves superior for early breast Ca

Article

Adding the anthracycline epirubicin to cyclophosphamide, methotrexate, and fluorouracil (CMF) is superior to CMF alone as adjuvant therapy for early breast cancer, regardless of estrogen-receptor status, tumor grade, or patient age.

Adding the anthracycline epirubicin to cyclophosphamide, methotrexate, and fluorouracil (CMF) is superior to CMF alone as adjuvant therapy for early breast cancer, regardless of estrogen-receptor status, tumor grade, or patient age.

The conclusion comes from two trials-The National Epirubicin Adjuvant Trial and the BR9601 trial-involving a total of 2,391 women with early breast cancer. After a median follow-up of 48 months, 2-year and 5-year relapse-free survival rates and 2-year and 5-year overall survival rates were significantly higher in the epirubicin group than in the CMF-alone group (91% vs. 85%; 76% vs. 69%; 95% vs. 92%; 82% vs. 75%, respectively; P<0.001). In addition, hazard ratios for relapse (or death without relapse) (0.69) and for death from any cause (0.67) were significant (P<0.001 for both).

While significantly more adverse effects occurred in the epirubicin group than in the CMF-alone group, they did not affect delivered dose intensity or quality of life.

Related Videos
Exploring the intersection of heart health and women's health | Image Credit: cedars-sinai.org
Unlocking the benefits of DHEA | Image Credit: drannacabeca.com
Unlocking the power of oxytocin | Image credit: drannacabeca.com
Revolutionizing menopause management: A deep dive into fezolinetant | Image Credit: uvahealth.com.
Deciding the best treatment for uterine fibroids | Image Credit: jeffersonhealth.org.
Clinical pearls of pediatric dermatology | Image Credit: profiles.ucsf.edu
Approaching inflammatory vulvovaginal diseases | Image Credit: profiles.ucsf.edu.
Related Content
© 2024 MJH Life Sciences

All rights reserved.